Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Neurobiological Tech (NTII) -- Ignore unavailable to you. Want to Upgrade?

To: Peter Silsbee who wrote (247)	1/29/1998 11:01:00 PM
From: Dr. John M. de Castro	Respond to of 1494

The fact that the Phase II Xerecept trial was initiated with the blessing of the clinical oncologists is a very positive sign. The oncologist only select a couple of trials each year to support and allow access to the brain tumor patients. That Xerecept was selected from a large number of applications submitted is a testimony to their belief that it is needed and to the high expectations the oncologists have for this drug. There are few other treatment options for these patients and Xerecept has a unique mode of action. So, IMO there will be a ready market for it if approved. The preclinical and Phase I/II clinical results for Xerecept are excellent. However, the results reported here have been known for a while. This is a simple announcement of official publication with the commensurate publication lags. Now for the puzzle of the day: Name for me another company with two very promising drugs in four Phase II trials and that is about to initiate a Phase III trial that has a market cap anywhere near the $6MM market cap of NTII. John de C